Mar. 3, 2026
Boston Scientific Execs Speak at Healthcare Conference
CEO Mike Mahoney and Chief Medical Officer Dr. Ken Stein present at TD Cowen's annual event.
Mar. 3, 2026
Amylyx Pharmaceuticals Focuses on Advancing Avexitide for Post-Bariatric Hypoglycemia
Company also provides updates on pipeline programs AMX0318, AMX0114, and AMX0035
Mar. 2, 2026
Agios Pharmaceuticals Highlights 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction
Company outlines upcoming clinical and regulatory milestones, discusses early commercial progress for thalassemia treatment.
Mar. 2, 2026
X4 Pharmaceuticals Announces Inducement Grants
Biotech firm issues stock options to new employees under Nasdaq rules
Feb. 26, 2026
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
Fourth quarter and full year 2025 revenue exceeded guidance
Feb. 25, 2026
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year
Feb. 25, 2026
Novo Nordisk Licenses Vivtex Tech for Up to $2.1 Billion to Deepen Obesity Push
Danish drugmaker aims to expand portfolio of next-generation obesity medicines with oral formulations
Feb. 25, 2026
Novo Nordisk Inks $2.1B Deal for Oral Obesity Drugs
Partnership with Vivtex to develop next-generation oral biologics for obesity and diabetes
Feb. 23, 2026
Metastat and Allurion Technologies Compared in Critical Survey
Analysts believe Allurion Technologies has stronger consensus rating and higher potential upside than Metastat.
Feb. 22, 2026
Ironwood Pharmaceuticals to Host Q4 and Full Year 2025 Investor Call
The biotech company will provide an update on its gastrointestinal and rare disease therapies.
Feb. 19, 2026
Massachusetts Hospital System Cuts 117 Corporate Jobs
Baystate Health cites financial pressures as it reduces its corporate workforce by less than 1%.
Feb. 15, 2026
Alnylam Pharmaceuticals Turns Profitable in Q4 2025
Biotech firm's strong financial results challenge bearish narratives
Feb. 14, 2026
Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782
CEO Jason Coloma discusses the company's genetics-driven approach to drug development at Guggenheim's Emerging Biotech Summit.
Feb. 14, 2026
American Well Focuses on Platform, Cost Cuts in Transformation
Digital health company narrows strategy, divests non-core activities to drive toward positive cash flow in Q4 2026
Feb. 13, 2026
Nxera Pharma Reports Solid 2025 Results, Focuses on Profitability
Biopharma company highlights commercial progress in Japan, pipeline milestones, and restructuring to enhance path to profitability
Feb. 13, 2026
American Well Focuses on Platform Amid Market Shift
Telehealth company narrows strategy, reduces costs, and eyes positive cash flow in 2026
Feb. 12, 2026
Southborough clinical research firm names new CEO
Veristat promotes Kim McLean Boericke to lead the company as CEO
Feb. 12, 2026
Akebia Therapeutics Highlights Dialysis Push, New Dosing Plan, and Rare Kidney Pipeline
Biotech firm outlines commercial priorities and pipeline progress at industry summit
Feb. 11, 2026
Polsinelli Expands Boston Presence with Healthcare Litigator Angelini
Veteran attorney Laura Angelini joins firm's healthcare litigation practice
Feb. 11, 2026
Trinity Ranked Top Health Sciences Consulting Firm in 2026 Vault Consulting Rankings
Global life sciences commercialization leader recognized as one of the world's most prestigious consulting firms
